CALIX, INC 10-Q

ITEM 5. Other Information During the three months ended March 28, 2026, no director or officer of us (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted , terminated or modified a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K, except as follows: On February 17, 2026 , Cory Sindelar , Chief Financial Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Sindelar 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Sindelar 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 256,000 shares of Common Stock, at specific market prices, commencing on July 1, 2026, and continuing until all such options are exercised and the underlying shares are sold, or May 31, 2027 , whichever comes first. On February 17, 2026 , Shane Eleniak , Chief Product Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Eleniak 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Eleniak 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 364,000 shares of Common Stock, at specific market prices, commencing on May 19, 2026, and continuing until all such options are exercised and the underlying shares are sold, or October 30, 2026 , whichever comes first. On February 19, 2026 , Michael Weening , Director, President and Chief Executive Officer of the Company, adopted a Rule 10b5-1 trading arrangement (the “Weening 10b5-1 Plan”) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The Weening 10b5-1 Plan allows for the contemporaneous exercise of options and sale of up to 397,100 shares of Common Stock, at specific market prices, commencing on May 21, 2026, and continuing until all such options are exercised and the underlying shares are sold, or February 19, 2027 , whichever comes first. 45 Table of Contents ITEM 6. Exhibits Exhibit Number Description 3.1 Amended and Restated Certificate of Incorporation of Calix, Inc. (filed as Exhibit 3.3 to Amendment No. 7 to Calix’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 23, 2010 (File No. 333-163252) and incorporated by reference). 3.2 Amended and Restated Bylaws of Calix, Inc. (filed as Exhibit 3.5 to Amendment No. 7 to Calix’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on March 23, 2010 (File No. 333-163252) and incorporated by reference). 31.1 Certification of Chief Executive Officer of Calix, Inc. Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Chief Financial Officer of Calix, Inc. Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certification of Chief Executive Officer and Chief Financial Officer of Calix, Inc. Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS XBRL Instance Document 101.SCH XBRL Taxonomy Extension Schema Document 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document 101.DEF XBRL Taxonomy Extension Definition Linkbase Document 101.LAB XBRL Taxonomy Extension Label Linkbase Document 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document 46 Table of Contents SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CALIX, INC. (Registrant) Date: April 22, 2026 By: /s/ Michael Weening Michael Weening President and Chief Executive Officer (Principal Executive Officer) Date: April 22, 2026 By: /s/ Cory Sindelar Cory Sindelar Chief Financial Officer (Principal Financial Officer) 47